Cargando…

TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients

Aim: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fariña-Sarasqueta, A., Gosens, M. J. E. M., Moerland, E., van Lijnschoten, I., Lemmens, V. E. P. P., Slooter, G. D., Rutten, H. J. T., van den Brule, A. J. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2010
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605551/ https://www.ncbi.nlm.nih.gov/pubmed/20966539 http://dx.doi.org/10.3233/ACP-CLO-2010-0526

Ejemplares similares

A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer
por: van de Schoot, L., et al.
Publicado: (2007)

Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting
por: Moerland, Elna, et al.
Publicado: (2006)

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer
por: van den Broek, Evert, et al.
Publicado: (2018)

A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
por: Baars, A, et al.
Publicado: (2002)

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

2nd TS Workshop
por: Collective
Publicado: (2005)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS Axis in hepatocellular carcinoma
por: Gu, Yan-jiao, et al.
Publicado: (2015)

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
por: Bonin, Serena
Publicado: (2015)

TPMT and DPD Polymorphisms: Efficient Screening Method for Indian Patients Considering Taking Thiopurine and 5-FU Drugs
por: Ashavaid, T. F., et al.
Publicado: (2009)

Lumican and Versican Are Associated with Good Outcome in Stage II and III Colon Cancer
por: de Wit, Meike, et al.
Publicado: (2012)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
por: Schippinger, W, et al.
Publicado: (2005)

E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy
por: Sulzyc-Bielicka, Violetta, et al.
Publicado: (2016)

Evaluation of TS and ENOSF1 Variants as a Biomarker in Response to Neoadjuvant Chemotherapy based on 5FU in Gastric Cancer Patients
por: Arjmandi, Khadijeh, et al.
Publicado: (2022)

Radical Resection After IORT-Containing Multimodality Treatment is the Most Important Determinant for Outcome in Patients Treated for Locally Recurrent Rectal Cancer
por: Dresen, Raphaëla C., et al.
Publicado: (2008)

Deletion of Chromosome 4q Predicts Outcome in Stage II Colon Cancer Patients
por: Brosens, R. P. M., et al.
Publicado: (2010)

ChemTS: an efficient python library for de novo molecular generation
por: Yang, Xiufeng, et al.
Publicado: (2017)

NMR-TS: de novo molecule identification from NMR spectra
por: Zhang, Jinzhe, et al.
Publicado: (2020)

A Good Practice Guide for Organizing the Scientific Program of International Conferences
por: Aljazeeri, Isra, et al.
Publicado: (2023)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

S5.3b Fungal spores: Initiators of colonization and infection
por: Baltussen, Tim, et al.
Publicado: (2022)

Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer
por: Sarasqueta, C., et al.
Publicado: (2019)

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients
por: Mesker, Wilma E., et al.
Publicado: (2009)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Endoscopic full thickness resection for early colon cancer in Lynch syndrome
por: Langers, Alexandra M. J., et al.
Publicado: (2019)

3rd TS Workshop
por: Béjar-Alonso, I, et al.
Publicado: (2008)

First Case of Topical 5-FU Therapy for Cutaneous Metastasis in a Patient with Colon Cancer
por: Ahmed, Gulrayz, et al.
Publicado: (2020)

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery
por: Simkens, Geert A., et al.
Publicado: (2016)

Radiotherapy Late Effects and Osteogenesis Imperfecta: Dos and Don'ts in Clinical Practice
por: Lodeweges, Joyce E., et al.
Publicado: (2019)

Prognosis of mucinous colon cancer is determined by histological biomarkers rather than microsatellite instability
por: van Zwam, Peter H., et al.
Publicado: (2022)

Whatever you are, be a good one: to get from good to great, you must learn how to get good
por: Emery, Stewart, et al.
Publicado: (2010)

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer
por: Li, Peilong, et al.
Publicado: (2017)

lncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer
por: Li, Peilong, et al.
Publicado: (2020)

Multi Parameter Flow Cytometric Assessment of Regenerative Epidermis with Special Reference to the Antiproliferative Effect of Occlusion
por: van Rossum, M. M., et al.
Publicado: (1998)

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
por: Cassidy, J, et al.
Publicado: (2006)

Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer
por: Fariña Sarasqueta, Arantza, et al.
Publicado: (2013)

PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy
por: Chen, Jian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m1mlo67ge9q5i49phkhghbl4ns